EmiSense Technologies Announces Closing of Third Round of Funding

EmiSense Technologies, LLC today announced it has closed its third round of funding. The investment round was led by strategic investor 9th Street Investments. EmiSense will use the US $6.5M in new funding to launch products, continue research and development, and support validation testing with global customers.

EmiSense PMTrac Particulate Matter Sensor. (PRNewsFoto/EmiSense Technologies, LLC)

"We are very happy to receive the investment and validation of our technology and business model," states Patrick Thompson , CEO of EmiSense. "The investment underlines the great progress we have made since the company was founded in 2009.

"EmiSense continues to hit critical technology milestones, and we are pleased to support the next stage in the company's development," states Doug Coors , Manager at 9th Street Investments, and Executive VP of CoorsTek.

EmiSense is developing improved electrostatic Particulate Matter (PM, or soot) sensors, simplified NOx (oxides of nitrogen, or smog) sensors, exhaust and intake oxygen sensors, and hydrocarbon sensors. "Right now, our primary focus is on the PMTrac® technology," explains Mr. Thompson. "Combustion-generated nanoparticles are a major air-quality and health concern all over the world. Current technologies are struggling to meet the regulatory deadlines just a few years away. PMTrac® delivers a combination of durability, sensitivity, and low cost to meet the needs of industry," he continues.

Clean diesel demand, including both on-road and off-road applications, are the major near-term drivers for smart sensors, while direct-injected gasoline engines are also expected to benefit from sensing technology breakthroughs. "One little-advertised byproduct of downsizing and turbo-charging is, while it produces greatly improved efficiency, it may also increase particulate matter output, and must be tightly monitored and optimally managed with closed-loop direct sensing."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.